|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience显示文摘 | Wigdan Al-Sukhni Ayelet Borgida Heidi Rothenmund Spring Holter Kara Semotiuk Robert Grant Stephanie Wilson Malcolm Moore Steven Narod Kartik Jhaveri Masoom Haider Steven Gallinger | 2012 | Journal of Gastrointestinal Surgery2012，，4： | 3 |
| 2 | Meta-analysis of new genome-wide association studies of colorectal cancer risk显示文摘 | Ulrike Peters Carolyn M. Hutter Li Hsu Fredrick R. Schumacher David V. Conti Christopher S. Carlson Christopher K. Edlund Robert W. Haile Steven Gallinger Brent W. Zanke Mathieu Lemire Jagadish Rangrej Raakhee Vijayaraghavan Andrew T. Chan Aditi Hazra Dav | 2012 | Human Genetics2012，，2： | 2 |
| 3 | Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry显示文摘AIM: To investigate the survival of individuals with colorectal cancer (CRC) with inflammatory bowel disease (IBD-associated CRC) compared to that of individuals without IBD diagnosed with CRC. METHODS: Epidemiologic, clinical, and follow-up data were obtained from the Colon Cancer Family Registry (Colon CFR). IBD-associated cases were identified from self-report of physician diagnosis. For a subset of participants, medical records were examined to confirm self-report of IBD. Cox proportional hazards regression was applied to estimate adjusted hazard ratios (aHR) and 95%CI of mortality, comparing IBD-associated to non-IBD-associated CRC, adjusted for age at CRC diagnosis, sex, Colon CFR phase, and number of prior endoscopies. Following imputation to complete CRC stage information, adjustment for CRC stage was examined. RESULTS: A total of 7202 CRC cases, including 250 cases of IBD-associated CRC, were analyzed. Over a twelve year follow-up period following CRC diagnosis, 2013 and 74 deaths occurred among non-IBD associated CRC and IBD-associated CRC patients, respectively. The difference in survival between IBD-associated and non-IBD CRC cases was not statistically significant (aHR = 1.08; 95%CI: 0.85-1.36). However, the assumption of proportional hazards necessary for valid inference from Cox regression was not met over the entire follow-up period, and we therefore limited analyses to within five years after CRC diagnosis when the assumption of proportional hazards was met. Over this period, there was evidence of worse prognosis for IBD-associated CRC (aHR = 1.36; 95%CI: 1.05-1.76). Results were similar when adjusted for CRC stage, or restricted to IBD confirmed in medical records. CONCLUSION: These results support the hypothesis that IBD-associated CRC has a worse prognosis than non-IBD-associated CRC. | Scott V Adams Dennis J Ahnen John A Baron Peter T Campbell Steven Gallinger William M Grady Loic LeMarchand Noralane M Lindor John D Potter Polly A Newcomb | 2013 | World Journal of Gastroenterology2013，19，21： | 2 |
| 4 | Presence of phthalates in gastrointestinal medications: Is there a hidden danger?显示文摘Pharmaceutical companies that produce gastrointestinal(GI)medications often utilize phthalates for their ability to localize medication release.Commonly prescribed GI medications that may utilize phthalates are 5-Aminosalicylates,proton pump inhibitors,and pancreatic enzymes.Our understanding of the cumulative health effects of phthalates from medications remains unclear,and there is increasing evidence that phthalates are not harmless.Experimental studies in animals have shown that phthalates,specifically dibutyl phthalate and Di-(2-ethyl-hexyl)phthalate,have the potential to alter and/or inhibit reproductive biology and in utero development.Despite the lack of definitive human data,many cohort and cross-sectional studies demonstrate concerning associations between phthalates and poor health status,specifically developmental problems.Longitudinal studies and studies with larger sample sizes are required to determine whether phthalates actually cause negative health consequences.It is also important that physicians regularly review and discuss with patients the medicinal ingredients in their medications and supplements,specifically in pregnant woman with inflammatory bowel disease. | Zane R Gallinger Geoffrey C Nguyen | 2013 | World Journal of Gastroenterology2013，19，41： | 2 |
| 5 | Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the canadian national enhanced cancer surveillance system 显示文摘 | Frise S Kreiger N Gallinger S | 2006 | Ann Epidemiol2006，16，12： | 1 |
| 6 | A human colon cancer cell capable of initiating tumour growth in immunodefieient mice 显示文摘 | O'Brien CA Pollett A Gallinger S | 2007 | Nature2007，445，7123： | 1 |
| 7 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice显示文摘 | O'BEIEN C A POLLETT A GALLINGER S | 2007 | Nature2007，445，4： | 1 |
| 8 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice显示文摘 | OBRIEN C A POLLETT A GALLINGER S | 2007 | Nature2007，445，7123： | 1 |
| 9 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice显示文摘 | O'Brien C A Pollett A Gallinger S | 2007 | Nature2007，445，： | 1 |
| 10 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice显示文摘 | O′Brien CA Pollett A Gallinger S | | 0，，7123： | 1 |
| 11 | A human colon cancer cell capable of initiating tumor growth in immunodeficient mice显示文摘 | O'Brien CA Pollett A Gallinger S | | 0，，04： | 1 |
| 12 | High protein and total lipid concentration are associated with reduced metastablity of bile in an early stage of cholesterol gallstone formation显示文摘 | Strasberg SM Gallinger S Gallinger S | 1990 | Gastroenterology1990，98，3： | 1 |
| 13 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice 显示文摘 | O' Brien CA Pollett A Gallinger S | 2007 | Nature2007，445，7123： | 1 |
| 14 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice 显示文摘 | O'Brien CA Pollett A Gallinger S | 2007 | Nature2007，45，4： | 1 |
| 15 | Changing causes of mortality in patients with familial adenomatous polyposis显示文摘 | Lance A. Belchetz M.D. Theresa Berk M.S.S.A. Bharati V. Bapat Ph.D. Zane Cohen M.D. Steven Gallinger M.D | 1996 | Diseases of the Colon & Rectum1996，，4： | 1 |
| 16 | Activation of Notch signaling in human colon adenocarcinoma显示文摘 | Michael Reedijk Silvia Odorcic Hui Zhang Runjan Chetty Carsten Tennert Brendan Dickson Gina Lockwood Steven Gallinger Sean Egan | 2008 | International Journal of Oncology2008，，： | 1 |
| 17 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice 显示文摘 | O'Brien CA Pollett A Gallinger S | 2007 | Nature2007，445，7123： | 1 |
| 18 | A human colon cancer cell capable of initiating tumour growth in immunodefi- cient mice显示文摘 | O'Brien C A Pollett A Gallinger S | 2007 | Nature2007，445，7123： | 1 |
| 19 | A human colon cancer cell capable of initiating tumour growth in immunodeficient mice显示文摘 | O'Brien CA Gallinger S | 2007 | Nature2007，445，7123： | 1 |
| 20 | A human colon cancer cell capable of initiating tumour growth in im- munodeficient mice显示文摘 | O'Brien CA Pollett A Gallinger S | 2007 | Nature2007，445，7123： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员